Opinion|Videos|September 4, 2024

Safety and Efficacy of GnRHa Treatments in Central Precocious Puberty

Author(s)Karen O. Klein, MD, Jill Samis, MD , Aviva B. Sopher, MD, MS

The panel examines the efficacy and safety profiles of gonadotropin-releasing hormone analogue (GnRHa) treatments in managing Central Precocious Puberty.

Episodes in this series

3 KOLs are featured in this series.

EP. 1 Overview Of Central Precocious Puberty

3 KOLs are featured in this series.

EP. 2 Diagnosis of Central Precocious Puberty and its Psychosocial Impact

3 KOLs are featured in this series.

EP. 3 Early Diagnosis and Treatment for Central Precocious Puberty

3 KOLs are featured in this series.

EP. 4 Treatment Options for Central Precocious Puberty

3 KOLs are featured in this series.

EP. 5 Safety and Efficacy of GnRHa Treatments in Central Precocious Puberty

3 KOLs are featured in this series.

EP. 6 Individualized Management of Central Precocious Puberty

3 KOLs are featured in this series.

EP. 7 Central Precocious Puberty Treatment Starts, Discontinuations and Misconceptions

3 KOLs are featured in this series.

EP. 8 Central Precocious Puberty in Male Patients

3 KOLs are featured in this series.

EP. 9 Recommendations and Outlook for Central Precocious Puberty

Video content above is prompted by the following:

What are long-term efficacy and safety data associated with gonadotropin releasing hormone analogue (GnRHa) treatment?

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Family history alone may not prompt type 1 diabetes screening, survey finds | Image Credit: © Africa Studio - stock.adobe.com

Family history alone may not prompt type 1 diabetes screening, survey finds

ByMorgan Ebert, Executive Editor

July 30th 2026

4 Experts are featured in this series

RSV Prevention: Final Reflections and a Vision for the Future

ByFlor M. Munoz, MD, MSc,C. Buddy Creech, MD, MPH,Eric Simões, MD,Tina Q. Tan, MD, FAAP, FIDSA, FPIDS

July 20th 2026

4 Experts are featured in this series

RSV Prevention and Vaccine Hesitancy: Building Long-Term Communication

ByFlor M. Munoz, MD, MSc,C. Buddy Creech, MD, MPH,Eric Simões, MD,Tina Q. Tan, MD, FAAP, FIDSA, FPIDS

July 20th 2026

4 Experts are featured in this series

RSV Immunization Rates and Vaccine Hesitancy: Practical Strategies for Clinicians

ByFlor M. Munoz, MD, MSc,C. Buddy Creech, MD, MPH,Eric Simões, MD,Tina Q. Tan, MD, FAAP, FIDSA, FPIDS

July 13th 2026

4 Experts are featured in this series

RSV and the Challenge of Reinfection: Long-Term Prevention Perspectives

ByFlor M. Munoz, MD, MSc,C. Buddy Creech, MD, MPH,Eric Simões, MD,Tina Q. Tan, MD, FAAP, FIDSA, FPIDS

July 13th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

Building trust may be key to vaccine conversations with hesitant families

What Pediatricians Should Know About JAK Inhibitors Before Referral

Vaccine schedule overhaul raises concerns about delayed protection and access, says Ravi Jhaveri, MD

Eczema, delayed allergen introduction, and early antibiotics top list of childhood food allergy risk factors

Rethinking screen time for back to school